Navigation Links
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
Date:2/3/2009

DL(CO), or -- Death In the case of FVC or DL(CO), the decline must be confirmed at two consecutive visits at least 6 weeks apart. 3. Categorical assessment of absolute change from Baseline to Week 72 in percent predicted FVC 4. Change from Baseline to Week 72 in dyspnea measured by the University of California at San Diego Shortness-of-Breath Questionnaire (UCSD SOBQ) 5. Change from Baseline to Week 72 in the percent predicted Hb-corrected DL(CO) 6. Change from Baseline to Week 72 in the worst oxygen saturation by pulse oximetry (SpO2) measurement observed during the Six-Minute Walk Test 7. Change from Baseline to Week 72 in distance walked in the Six- Minute Walk Test

Regarding RECAP, all eligible patients from CAPACITY have been enrolled in this on-going open-label roll-over study from CAPACITY to evaluate the long-term safety of pirfenidone in patients with IPF.

The results of CAPACITY will be presented at the 2009 International Conference of the American Thoracic Society (ATS) in San Diego, and InterMune plans to publish the results of CAPACITY in a peer-reviewed journal.

About Pirfenidone

Preclinical and in-vitro evidence had shown that pirfenidone inhibits collagen synthesis, down-regulates profibrotic cytokines and decreases fibroblast proliferation. Prior to the current results, data were presented from one Phase 3 study and four Phase 2 clinical trials in more than 400 patients which suggested that pirfenidone may positively affect lung function and disease progression in patients with IPF. In those clinical studies, pirfenidone was generally safe and well tolerated with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms. In October of 2008, pir
'/>"/>

SOURCE InterMune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at J.P. Morgan Healthcare Conference
2. InterMune to Present at Deutsche Bank Biotech Boston Confab
3. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
4. InterMune to Release Third Quarter 2008 Financial Results on November 6
5. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
6. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
7. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. InterMune to Present at BMO Healthcare Conference
11. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015 VG Life Sciences, Inc., ... autoimmune and infectious diseases, announced that the U.S. ... important new composition of matter patent covering methods ... of CLIP. U.S. Patent No. ... Life Sciences, VG1177, a synthetic peptide which has ...
(Date:2/28/2015)... Increasing its efforts to resolve the GMO ... episodes of The GMO TRUTH podcast on both ITunes and ... continues its mission to discover the truth and change the ... “uncover the truth about the GMOs in our food supply,” ... Podcast is an expansion of the documentary/investigative film-making methodology in ...
(Date:2/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) ... of Trypsin" report to their offering. , ... providing comprehensive data on Trypsin globally and regionally ( ... North America , Latin America ... Trypsin This report focuses on three primary areas; ...
(Date:2/27/2015)... 27, 2015 FamilyFarms Group is pleased ... of State Line Farms, received the 2015 Tomorrow’s Top ... under the age of 35, who has demonstrated excellence ... honor to win the Tomorrow's Top Producer Horizon Award. ... the Top Producer Award and learning from their experiences. ...
Breaking Biology Technology:VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Global Market Report of Trypsin 2014-2018 2Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... Yongye Biotechnology,International, Inc. (OTC Bulletin Board: YGYB; "Yongye" ... of nutrients for plants and,animals, located in the ... management will present at the upcoming Roth 21st ... , The date, time, ...
... today announced the appointment of Babatunde A. Otulana, M.D., ... medical officer.Dr. Otulana, 52, will provide medical as well ... it moves forward with the development of AerovantTM for ... has more than 20 years of experience in pulmonary ...
... Stock Exchange Symbol: LRILAVAL, QC, Feb. 9 /PRNewswire-FirstCall/ - ... "Company"), a Canadian based global non-clinical contract research organization ... Officer of the Company, will be presenting at the ... 11, 2009 at 9.30 am at the Waldorf Astoria ...
Cached Biology Technology:Yongye Biotechnology to Present at Roth Conference 2Yongye Biotechnology to Present at Roth Conference 3Aerovance Appoints Babatunde A. Otulana, M.D., as Chief Medical Officer 2
(Date:2/19/2015)... Feb .19, 2015 Research and Markets ... of the "Military Electro-Optical / Infrared Systems ... by Platform - Forecast to 2020" report ... electro-optical/infrared systems market is expected to reach $16.35 ... 7.71%. This report segments the military ...
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3
... of the Institute of Tropical Medicine (ITG) discovered a parasite ... but at the same time had become better in withstanding ... in developing a superbug. For it appears the battle against ... "To our knowledge it is the first time such a ...
... The Danish National Advanced Technology Foundation is donating ... brings together Denmark,s leading players within the sustainable use ... Mller Mrsk, Novozymes, Haldor Topse, Man Diesel & Turbo ... for the parties, joint research aimed at developing specific ...
... in recent years that wild chilies develop their trademark pungency, or ... seeds. But that doesn,t explain why some chilies are hot and ... growing in dry areas need more water to produce as many ... a threat in dryer environments so chilies in those areas are ...
Cached Biology News:Do our medicines boost pathogens? 2Do our medicines boost pathogens? 3New research platform paves way for future bio-based society 2To turn up the heat in chilies, just add water 2
See product name for description....
... Custom Production Service - Conjugation ... Conjugation Biotin Conjugation Fluorescein Isothiocyanate ... Conjugation Allophycocyanin Conjugation Alexa Fluor ... Alexa Fluor 405 Conjugation Rpe-Alexa ...
... Design , Customer Peptide Synthesis , 20 Amino Acid ... , 20 mg will return to customer for future usage ... 2 , Maintenance 102 days/each , ... x5 /each , Test bleed (app. 5 ...
Request Info...
Biology Products: